Updated prostate cancer screening guidelines emphasize benefits of early detection
New American Cancer Society guidelines go beyond one size fits all approach, focus on individual risk
3:30 PM
Author |
Recently updated guidelines from the American Cancer Society for prostate cancer screening aim to help detect cancer earlier before it spreads, reduce the risk of dying from the disease, and avoid aggressive treatment of prostate cancers that are not life threatening.
The updates are based on evolving evidence that prostate-specific antigen (PSA)-based screening is effective and marks the first update to the ACS guidelines since 2010.
“The updated ACS guidelines are an important step forward — they signal that we can no longer afford a one size fits all approach to prostate cancer screening,” said Simpa Salami, M.D., M.P.H., David A. Bloom Professor of Urology at Michigan Medicine and a urologist at the University of Michigan Rogel Cancer Center and Weiser Center for Prostate Cancer.
The updated ACS recommendations for prostate cancer screening include:
PSA-based screening every two years for men aged 50-69 years who are at average risk for prostate cancer.
Men at high risk, including Black men and non-Black men with a strong family history of prostate cancer (either a first-degree relative diagnosed before age 65 or multiple first-degree relatives diagnosed at any age) should undergo yearly PSA-based screening from age 45-69 years.
Non-Black men with a single first-degree relative diagnosed at age 65 or older should be screened every two years from ages 45-69.
For men aged 70-74, individualized decision making on continuing screening in consultation with a health care provider is recommended.
Men with a confirmed elevated PSA should be offered testing by magnetic resonance imaging (MRI) and/or a validated biomarker to help guide biopsy decisions.
PSA screening is not recommended for men aged 75 and older.
Men diagnosed with low risk prostate cancer should be offered active surveillance as the initial management option.
“At the Weiser Center, our research is focused on the next frontier: not just detecting cancer earlier but detecting it smarter,” Salami said. “By combining MRI with novel biomarkers, we aim to give every man — regardless of race or background — a more precise, personalized path to diagnosis of clinically significant prostate cancer.”
According to Salami, one of the challenges for health care providers when consulting guidelines is the differences in recommendations among various organizations. The current update to the ACS guidelines for prostate cancer screening aligns well with those of the American Urological Association/Society of Urologic Oncology, the National Comprehensive Cancer Network, the Prostate Cancer Foundation, and the European Association of Urology. This will hopefully enable implementation and adherence across the board, he said.
The bottom line for patients: Talk to your doctor about PSA-based screening for prostate cancer and whether the time is right for you.
The full guideline update is published in CA: A Cancer Journal for Clinicians.
Sign up for Health Lab newsletters today. Get medical tips from top experts and learn about new scientific discoveries every week.
Sign up for the Health Lab Podcast. Add us wherever you listen to your favorite shows.
Health Lab
Explore thousands of health news & research stories by visiting the Health Lab homepage for more.
Media Contact
Public Relations
Department of Communication at Michigan Medicine
In This Story
Simpa S Salami, MD, MPH
Associate Professor
Related
New Subtype of Prostate Cancer
Following the science from prostate cancer’s “on switch” to the Sjöberg Prize
Stay Informed
Want top health & research news weekly? Sign up for Health Lab’s newsletters today!
Featured News & Stories
Are you at risk of a genetic disease? Guidelines for testing should be updated, experts say
How have diagnostic and treatment decisions for prostate cancer changed in recent years?
Immune system protein is a cancer killer on its own, new study shows
Online resources and coaching helped people seek genetic testing for cancer
‘Molecular glue’ stabilizes protein that inhibits development of non-small cell lung cancer and uterine cancer